Siga Technologies (NASDAQ:SIGA) Releases Earnings Results

Key Points

• Siga Technologies reported earnings of $0.49 earnings per share for the latest quarter, reflecting a return on equity of 25.21% and a net margin of 40.30%.
• The company's stock price is currently $6.60, with a market capitalization of $471.50 million and a price-to-earnings ratio of 9.85.
• Recently, Strs Ohio acquired a new stake in Siga Technologies, purchasing 30,200 shares valued at approximately $165,000, bringing institutional ownership to 55.40%.

Siga Technologies (NASDAQ:SIGA - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.49 EPS for the quarter, Zacks reports. The firm had revenue of $81.12 million for the quarter. Siga Technologies had a net margin of 45.73% and a return on equity of 40.97%.

Siga Technologies Stock Performance

NASDAQ SIGA traded up $1.37 on Thursday, reaching $8.63. The company's stock had a trading volume of 850,749 shares, compared to its average volume of 457,756. The stock has a market cap of $616.46 million, a PE ratio of 7.69 and a beta of 0.94. Siga Technologies has a twelve month low of $4.95 and a twelve month high of $12.83. The firm's 50 day moving average is $6.56 and its two-hundred day moving average is $6.10.

Institutional Trading of Siga Technologies

An institutional investor recently raised its position in Siga Technologies stock. Jane Street Group LLC increased its stake in Siga Technologies Inc. (NASDAQ:SIGA - Free Report) by 138.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 114,147 shares of the company's stock after purchasing an additional 66,265 shares during the quarter. Jane Street Group LLC owned approximately 0.16% of Siga Technologies worth $626,000 at the end of the most recent reporting period. 55.40% of the stock is currently owned by institutional investors and hedge funds.

Siga Technologies Company Profile

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.